Dihydrotanshinone I enhanced BRAF mutant melanoma treatment efficacy by inhibiting the STAT3/SOX2 signaling pathway

Dihydrotanshinone I enhanced BRAF mutant melanoma treatment efficacy by inhibiting the STAT3/SOX2 signaling pathway

BackgroundThe Food and Drug Administration has approved the Serine/threonine-protein kinase B-raf (BRAF) inhibitor and Mitogen-activated extracellular signal-regulated kinase (MEK) inhibitor combo as the first-line treatment for individuals with metastatic melanoma, although the majority of these pa...

Full description

Saved in:
Bibliographic Details
Main Authors: Xing Luo, Yi Duan, Jinwei He, CongGai Huang, Jun Liu, Yifan Liu, Mengdei Xu, Qiong Dai, Zhihui Yang
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Oncology
Subjects:
BRAF mutation
dihydrotanshinone I
melanoma
MAPK pathway
STAT3
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2025.1429018/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items